Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 12/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29290251 | 0.82 | TSHR (0.40) | NAMPTHTTHSD17B10CYP11B1CYP11B2 | |
| SCHEMBL20342093 | 0.79 | — | — | |
| SCHEMBL9854852 | 0.74 | NAMPT (0.35) | NAMPTACACBIMPDH2 | |
| SCHEMBL31063346 | 0.72 | NAMPT (0.34) | NAMPTHSP90AB1CYP11B1CYP11B2IMPDH2 | |
| SCHEMBL6274565 | 0.70 | NAMPT (0.36) | NAMPT | |
| SCHEMBL30421208 | 0.70 | NAMPT (0.49) | NAMPT | |
| SCHEMBL17581887 | 0.70 | HSP90AB1 (0.50) | HSP90AB1CYP4F2CYP4A11HTTHSD17B10 | |
| SCHEMBL3137449 | 0.70 | — | — | |
| SCHEMBL10731601 | 0.69 | NAMPT (0.45) | NAMPTCYP4F2CYP4A11HSD17B10 | |
| SCHEMBL873455 | 0.69 | HSP90AB1 (0.38) | HSP90AB1CYP4F2CYP4A11HTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188075-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | THE BROAD INSTITUTE, INC. | 2025-06-12 | — | — | US | disclosed |
| EP-4469457-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | The Broad Institute Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023147015-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | THE BROAD INSTITUTE, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147015-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | THE BROAD INSTITUTE, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-9624200-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-04-18 | — | — | US | disclosed |
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. | 2015-03-26 | — | — | US | disclosed |
| US-8927546-B2 | Therapeutic piperazines | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2015-01-06 | — | — | US | disclosed |
| EP-2643000-A2 | THERAPEUTIC PIPERAZINES | Dart Neuroscience (Cayman) Ltd (KY) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012040258-A2 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087645-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | NAMPT 2458/4885HSP90AB1 2564/4885CYP4F2 1529/4885 |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | NAMPT 2458/4885HSP90AB1 2564/4885CYP4F2 1529/4885 |
| US-20250188075-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | CSNK1A1, CSNK2A1, CSNK1A1L | NAMPT 2400/4885HSP90AB1 1962/4885CYP4F2 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.